Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schmidt

Showing results (301-310 of 326) with videos related to

Pageof 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION TrialKarolina Edlund, Katrin Madjar, Antje Lebrecht, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumorsMarcus Schmidt, Birte Hellwig, Seddik Hammad, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022Maggie Banys-Paluchowski, Marc Thill, Thorsten Kühn, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022Marc Thill, Diana Lüftner, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|September 28, 2019
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019Marc Thill, Christian Jackisch, Wolfgang Janni, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Pageof 33

Showing results (301-310 of 326) with videos related to

Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION TrialKarolina Edlund, Katrin Madjar, Antje Lebrecht, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumorsMarcus Schmidt, Birte Hellwig, Seddik Hammad, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022Maggie Banys-Paluchowski, Marc Thill, Thorsten Kühn, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022Marc Thill, Diana Lüftner, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|September 28, 2019
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019Marc Thill, Christian Jackisch, Wolfgang Janni, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Pageof 33